SARA W. KOBLITZ is a director at Hyman Phelps & McNamara where she advises FDA-regulated clients on a range of issues with a particular focus on Hatch-Waxman patent and exclusivity, biosimilars, and the Orange Book. Ms. Koblitz has authored many Citizen Petitions and has worked extensively on Hatch-Waxman litigation. Additionally, she helps drug and device manufacturers in various stages of product development and guides clients through the applicable regulatory requirements with respect to applications and submissions, potential exclusivities, promotional issues, and post-marketing requirements. She has worked with companies of all sizes, from start-ups to fortune 500 companies. Prior to joining Hyman Phelps & McNamara, Ms. Koblitz practiced at a major intellectual property firm, where she counseled clients on the Hatch-Waxman Act and other areas of FDA regulation. Prior to that she worked on general FDA regulatory matters at an AmLaw 100 firm. While in law school, Ms. Koblitz clerked at the FDA Office of Policy and the Humane Society of the United States.
